Dox01 0013 01
Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 25021-207
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 25021-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Dox01 0013 02
Hazard Ratio (HR) is a statistical measure used in clinical trials to compare the probability of an event occurring in different treatment groups. The following text provides information on the hazard ratios observed in several trials, including NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. It also mentions that doxorubicin (DOXO) showed better results than CMF in six studies, but in one study, DOXO was found to be worse than CMF, with a boundary of non-inferiority with CMF at 1.06 (75% of CMF effect retained).*
Dox01 0013 03
The given text mentions different trials and their corresponding hazard ratios for the comparison of Doxo (a type of chemotherapy) with CMF (Cyclophosphamide, Methotrexate, and Fluorouracil). However, the text is incomplete and does not provide enough information to generate a useful description.*
Dox01 0013 04
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
